SIRO Clinpharm announces alliance with DreamCIS CRO

SIRO Clinpharm, a Contract Research Organization (CRO) with a presence in India, Western and Central Eastern Europe, and the United States today announced its alliance with DreamCIS Inc., a leading CRO based in Seoul, South Korea.  

DreamCIS has nearly a decade of experience in offering clinical research services to pharmaceutical companies, bio venture companies, medical device manufacturers, and functional food producers. Their services includes Clinical Trial Management, Pharmacovigilance, Post Marketing Surveillance (PMS), Data Management, Biostatistics and Quality Assurance services.

SIRO Clinpharm has been in the arena of contract clinical research for more than 14 years, conducting ICH GCP compliant clinical trials for its global clientele. In addition to the services that DreamCIS provides, SIRO's service list also includes Medical Writing, Clinical Trials Supplies Management, Feasibility and Patient Planning.

"This pact will help us on one hand to build a strong competitive advantage in the Asia Pacific region, while on the other hand it will create a sustainable value for our existing as well as potential customers," said Ajit Nair, Ph.D., President, India. He further added that, "Our goal is to offer a wider platform of patient recruitment capabilities from the Asia Pac region for our global client base."

"We are one of the leading and fastest growing CROs in South Korea. However, looking at the increasing number of global clinical trials and the rapid growth in the Asian clinical trials market, we were looking at associating ourselves with a CRO having a global exposure; not only from business vertical perspective but also from the perspective of moving up on the learning curve. I think our mutually beneficial alliance with SIRO is a definite step in this direction," said Won-Jung Choi, President, DreamCIS Inc.    

"Korea is a rapidly growing clinical trials market due to various advantages it offers like pre-approved and well-equipped clinical trial sites, trained professionals, and transparent and efficient regulatory processes," said Chetan Tamhankar, PhD, SIRO's Chief Executive Officer. "We are confident this alliance will be of immense value to SIRO and widen our global service capabilities."